Main > > >ENDOCRINOLOGY. (ENDO.)

---

Diabetes. C-peptide Assay.
C-peptide measurement is used in the diagnosis and management of different types of diabetes and related conditions. C-peptide is produced and secreted by pancreatic beta cells. Its measurement aids in differentiating between type 1 diabetes, type 2 diabetes, Latent Autoimmune Diabetes (LADA) and Maturity Onset Diabetes of the Young (MODY). It is also used to detect absolute deficiency of insulin.i,ii In conjunction with insulin and glucose results, C-peptide measurement also helps differentiate between factitious hypoglycemia and endogenous hyperinsulinism caused by insulinoma or other disorders.
Commercially available in the U.S. and countries accepting CE Mark.
(*) Company : Ortho Clinical
Diagnostics.
TradeMark: VITROS®
UpDate: 2018. 03.09.




Diabetes. Glucose. 14 Day Flash Glucose
Monitoring System.
EU Approval Date : 2014. 09.03.
USA Approval Date: 2018. 07.27.
(*) Company : Abbott.
TradeMark: FreeStyle Libre
Web-Site : www.freestylelibre.us
UpDate: 2018. 07.28.




Diabetes. Glucose. Computer Based Monitoring of Blood Glucose Levels.
(*) Company; Patent APP.; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 08.08.




Diabetes. Hemoglobin A1c (HbA1c) Assay.
Diagnosis & Monitoring.
EU Approval Date : ?
USA Approval Date: 2018. 07.30.
(*) Company : Sekisui Diagnostics.
TradeMark: SEKURE
UpDate: 2018. 07.31/




Diabetes. Insulin. Delivery Pen. (U)
- USA Approval Date: 2016. 07.27.
(for Apple iOS)
- USA Launch Date : 2017. 12.14.
(for Apple iOS)
- USA Approval Date: 2018. 07.09.
(for Android)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.02.




Diabetes. Insulin. Pump. TouchScreen Insulin Pump+Mobile Continuous Glucose Monitoring (CGM) Integration.
EU Approval Date: 2018. 04.30.
USA Approval Date: 2017. 08.28.
(*) Companies:
- Dexcom
www.dexcom.com
- Tandem Diabetes Care Inc
www.tandemdiabetes.com/
TradeMarks:
- t:slim X2 (Tandem ..)
- Dexcom G5 (Dexcom ..)
UpDate: 2018. 05.01.




Diabetes. Insulin. Smart Sensor.
Easylog is a smart sensor that turns all classic pen injectors, disposable and reusable, into connected devices. Easylog captures key treatment information (dose, date, time) and transfers it to a monitoring mobile app. This innovative solution goes hand in hand with a dedicated application that aims to facilitate the life of patients monitoring their treatment.
EU Approval Date: 2017. 12.20.
(*) Company Available on Request.
UpDate: 2017. 12.21.




Diabetes. TREAT.: Insulin Aspart Injection 100 Units/mL.
USA Launch Date: 2018. 02.05.
(*) Company : Novo Nordisk.
TradeMark: Fiasp
Web-Site : www.fiasppro.com
UpDate: 2018. 02.06.




Diabetes. TREAT.: Insulin Glargine.
BioSimilar.
AU & EU Approval Date: 2018. 03.28.
(*) Companies: Mylan NV & Biocon Ltd
TradeMark: Semglee
UpDate: 2018. 03.29.




Diabetes. TREAT.: Insulin Glargine.
Brand.
EU Approval Date : 2000. 06.09.
USA Approval Date: 2000. 04.20.
Two out of Three Formulation Patents on Multibillion-Dollar Drug are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan. (2018. 12.13)
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 12.14.




Diabetes. TREAT.: Insulin Lispro Injection.
MAN. blood sugar levels at mealtime.
EU Approval Date : 2017. 07.
USA Approval Date: 2017. 12.11.
(*) Company; TradeMark & Web-Site
Available on Request
UpDate: 2018. 03.18.




Diabetes Type 0I. Insulin Delivery Management. Monitoring Device.
EU Approval Date: 2018. 02.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 02.16.




Diabetes Type 0I. TREAT.: Dapagliflozin
Tablets.
Mechanism: SGLT2 Inhibition.
EU Approval Date: 2019. 03.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.23.




Diabetes Type II. TREAT.: Canagliflozin
Tablets.
CA Approval Date : 2014. 05.23.
USA Approval Date: 2013. 03.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.31.




Diabetes Type II. TREAT.: Dapagliflozin
Tablets.
Mechanism: SGLT2 Inhibition.
EU Approval Date : ?
USA Approval Date: 2014. 01.08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.23.




Diabetes Type II. TREAT.: Ertugliflozin Tablets.
Sodium-Glucose Co-Transporter 2 (SGLT2)- Inhibitor.
USA Approval Date: 2017. 12.19.
(*) Companies & TradeMark Available on Request
UpDate: 2017. 12.22.




Diabetes Type II. TREAT.: Exenatide 1/Week ER Injectable
Suspension 2 mg.
USA Approval Date: 2017. 10.23.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.11.




Diabetes Type II. TREAT.: Exenatide 1/Week ER Injectable
Suspension 2 mg.+Insulin Glargine Therapy (Basal Insulin).
USA Approval Date: 2018. 04.03.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 04.04.




Diabetes Type II. TREAT.: Semaglutide Injection 0.5 mg or 1 mg.
once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults.
USA Approval Date: 2017. 12.05.
USA Launch Date: 2018. 02.05.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 02.06.




Familial Chylomicronemia Syndrome (FCP)
TREAT.: Volanesorsen.
EU Approval Date : 2019. 05.07.
Scotland Launch Date: 2020. 11.09.
UK Launch Date : 2020. 09.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 01.11.




Growth Hormone Deficiency (GHD) in Adults. DIAG.: Macimorelin, an Orally available Ghrelin Agonist.
Macimorelin) stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Stimulated growth hormone levels are measured in four blood samples over ninety minutes after oral administration of Macimorelin for the assessment of growth hormone deficiency (“GHD”). Prior to the approval of Macimorelin, the historical gold standard for evaluation of AGHD was the insulin tolerance test (“ITT”), an intravenous test requiring many blood draws over several hours. The ITT procedure is inconvenient for patients and medical practitioners and may contraindicate in patients, such as those with coronary heart disease or seizure disorder, because it requires the patient to experience hypoglycemia to obtain an accurate result.
EU Approval Date: 2019. 01.16.
USA Approval Date: 2017. 12.20.
(*) Companies; Patents; TradeMark
& web-site Available on Request.
UpDate: 2020. 12.21.




Obesity. TREAT.: Phentermine.HCl 8 mg Tab.
USA Approval Date: 2016. 09.20.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2017. 12.13.




Progesterone API.
Launch Date: 2018. 03.06.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2018. 04.29.




Wilsons Disease. TREAT.: Trientine.HCl. GENERICS.
USA Launch Date: 2018. 02.09.
(*) Company: Teva Pharma.
UpDate: 2018. 02.10.




X–linked Hypophosphatemia (XLH). TREAT.:
BurosuMAb.
USA Approval Date: 2018. 04.17.
USA Launch Date: 2018. 04.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.08.


>ENDOCRINOLOGY. (ENDO.)'s products
This section has no products